Secretion of Noncomplexed ‘Big’ (10–18 kD) Forms of Insulin-Like Growth Factor-II by 12 Soft Tissue Sarcoma Cell Lines

The paraneoplastic production of pro-insulin-like growth factor-II (IGF-II) forms causes tumour hypoglycaemias and presumably also has an effect on tumour cell growth. We investigated the molecular weights of IGF-II forms and their ability to form complexes with IGF binding proteins (IGFBPs) in conditioned culture media (CM) from 12 paediatric soft tissue sarcoma (STS) cell lines and from two healthy fibroblast lines. Untreated CM were separated by size exclusion chromatography using biocompatible HPLC. Subsequently, IGF-II, IGFBP-2 and IGFBP-3 were determined in the HPLC fractions by specific RIAs. In the CM, IGF-II concentrations between 0.5 and 8.6 ng/106 cells were measured but no IGF-I was detectable. Parallel to this investigation, a high IGF-II mRNA level averaging 44.4 ± 29.7% was measured by semi-quantitative RT-PCR. The STS cell lines secreted a higher proportion of big-IGF-II forms reaching 10–18 kD (10–33% of the total IGF-II secreted) compared to the healthy fibroblasts (2.5–5%). At the same time, the proportion of IGF-II bound with IGFBP in complexes of 35– 70 kD and 150 kD was reduced by up to 85% in CM from tumour cells. The tumour cell lines apparently secrete a different spectrum of IGF-II forms than healthy fibroblasts. The reduced ability to form complexes with IGFBP and the higher molecular weight of the IGF-II forms produced by the tumour cells indicate that these forms could in fact be the known tumour-associated pro-IGF-II forms. Due to these characteristics, the big-IGF-II forms probably have an altered biological effect on the tumour cells when compared to IGF-II.

[1]  M. Elmlinger,et al.  Correlation of type I insulin-like growth factor receptor (IGF-I-R) and insulin receptor-related receptor (IRR) messenger RNA levels in tumor cell lines from pediatric tumors of neuronal origin , 1999, Regulatory Peptides.

[2]  D. Steiner,et al.  Post-translational Processing of the Insulin-like Growth Factor-2 Precursor , 1998, The Journal of Biological Chemistry.

[3]  M. Elmlinger,et al.  Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. , 1998, European journal of endocrinology.

[4]  M. Doebeli,et al.  High molecular weight forms of IGF-II ('big-IGF-II') released by Wilms' tumor cells. , 1997, European journal of endocrinology.

[5]  T. Vu,et al.  Increased Expression of the Insulin-like Growth Factor-II Gene in Wilms' Tumor Is Not Dependent on Loss of Genomic Imprinting or Loss of Heterozygosity* , 1996, The Journal of Biological Chemistry.

[6]  A Kondepudi,et al.  The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain. , 1996, Endocrinology.

[7]  R. Baxter.  The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. , 1996, Hormone research.

[8]  A. Hoeflich,et al.  Does the overexpression of pro-insulin-like growth factor-II in transfected human embryonic kidney fibroblasts increase the secretion of lysosomal enzymes? , 1995, European journal of biochemistry.

[9]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[10]  G. Schwartz,et al.  Glycosylated insulin-like growth factor II promoted expansion of granulocyte-macrophage colony-forming cells in serum-deprived liquid cultures of human peripheral blood cells. , 1993, Experimental Hematology.

[11]  W. Daughaday,et al.  Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum. , 1992, Journal of Clinical Endocrinology and Metabolism.

[12]  W. Daughaday,et al.  Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. , 1992, The Journal of clinical endocrinology and metabolism.

[13]  Y. Le Bouc,et al.  Abnormalities of insulin-like growth factor (IGF-I and IGF-II) genes in human tumor tissue. , 1992, Growth regulation.

[14]  J. Sussenbach,et al.  Structure and expression of the human insulin-like growth factor genes. , 1992, Growth regulation.

[15]  W. Daughaday,et al.  Tumor secretion of growth factors. , 1991, Endocrinology and metabolism clinics of North America.

[16]  W. Daughaday,et al.  Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals. , 1990, The Journal of laboratory and clinical medicine.

[17]  J. Fantini,et al.  Production of insulin‐like growth factor II (IGF‐II) and different forms of IGF‐binding proteins by HT‐29 human colon carcinoma cell line , 1990, Journal of cellular physiology.

[18]  P. Rotwein,et al.  Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. , 1988, The New England journal of medicine.

[19]  P. Zumstein,et al.  Amino acid sequence of a variant pro-form of insulin-like growth factor II. , 1985, Proceedings of the National Academy of Sciences of the United States of America.